Enhancing therapeutic efficacy in luminal androgen receptor triple-negative breast cancer: exploring chidamide and enzalutamide as a promising combination strategy.

Cancer Cell Int · 2024 · PMC11003165 · PMID 38594722

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Therefore, further exploration of the combination of HDACis with anti-androgen endocrine therapy for LAR-type TNBC is highly significant and promising.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.